about
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectivesAcute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
P50
Q34329186-61468054-D4A8-4049-9986-EC6D66D3AB34Q35001579-64CDCE27-B69D-4D92-890D-49197DE980AEQ36804215-D1B67555-F4C1-4241-AC2F-A2CD46FF4C88Q38146323-F1F939BC-D034-4467-83F0-7547AB3EA638Q39026376-63FDAB4D-D7B4-4F19-BCE9-760775B626A5Q39408105-2326D9DD-C2C9-4C1F-BE53-88876EBCDF9CQ41925285-CC1B7A86-2182-41F2-94C0-ACFE75556F3D
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-7327-418X
@en
name
Sarah Tettamanti
@ast
Sarah Tettamanti
@en
Sarah Tettamanti
@es
Sarah Tettamanti
@nl
type
label
Sarah Tettamanti
@ast
Sarah Tettamanti
@en
Sarah Tettamanti
@es
Sarah Tettamanti
@nl
prefLabel
Sarah Tettamanti
@ast
Sarah Tettamanti
@en
Sarah Tettamanti
@es
Sarah Tettamanti
@nl
P106
P1153
47761687300
P21
P31
P496
0000-0002-7327-418X